

MATERIAL CHANGE REPORT
Form 51-102F3

1. **Reporting Issuer**

Canntab Therapeutics Limited (the “**Issuer**”)
1 Adelaide Street East, Suite 801 Toronto,
Ontario, M5C 2V9

2. **Date of Material Change**

June 14, 2018.

3. **News Release**

A news release with respect to the material change referred to in this report was disseminated on June 14, 2018 through Newsfile and filed on the system for electronic document analysis and retrieval (SEDAR) at www.sedar.com.

4. **Summary of Material Change**

The Issuer has announced director resignation.

5. **Full Description of Material Change**

The material change is fully described in the news release attached hereto as Schedule "A".

6. **Reliance on Section 7.1(2) of National Instrument 51-102**

Not applicable.

7. **Omitted Information**

Not applicable.

8. **Executive Officer**

The senior officer who can answer questions regarding this report is Richard Goldstein, Chief Financial Officer. Mr. Goldstein can be reached at (416) 957-6303 or by email at info@canntab.ca.

9. **Date of Report**

June 22, 2018

Schedule "A"



Canntab THERAPEUTICS

CANNTAB ANNOUNCES DIRECTOR RESIGNATION

Toronto, June 14, 2018 (Newsfile Corp.) – Canntab Therapeutics Limited (CSE:PILL) (“**Canntab**” or the “**Company**”) announces that Sheldon Inwentash has resigned from the Company’s Board of Directors to pursue other opportunities. Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, “I would like to thank Sheldon for his valuable contributions to the Company and, on behalf of the Board, I wish him every success in his future endeavours.”

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab's mission is to put the "Medical" into medicinal cannabis!

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
info@canntab.ca

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.